Diabetic Foot Ulcers Treatment Market, By Product Type (Wound Care Dressings (Foam Dressing, Hydrocolloid Dressing, Hydrogel Dressing, Alginate Dressing, and Other Dressing), Biologics (Growth factors, Skin Graft, and Skin Substitutes), Wound Care Therapy Devices (Negative Pressure Wound Devices, Hyperbaric Oxygen Therapy, and Other Wound Care Therapy Devices), and Others), By Ulcers Type (Neuropathic Ulcers and Neuro-Ischemic Ulcers), By Distribution Channel (Hospitals, Clinics, Ambulatory Surgical Center, and Homecare Setting), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

High rate of diabetes

In the near future, a high prevalence of diabetes is anticipated to play a significant role in boosting demand for diabetic foot ulcer medications and propelling their market expansion. For example, according to data released by the National Center for Biotechnology Information in 2017, diabetic mellitus (D.M.) is one of the most prevalent metabolic disorders. It was estimated that approximately 20% of people worldwide and 5% of people in Europe suffer from D.M. In the near future, new product launches for treating diabetic foot ulcers are anticipated to accelerate market growth. For example, the U.S. Food and Drug Administration approved Integra LifeSciences Corporation's Omnigraft Dermal Regeneration Matrix in 2016 for a new use to cure certain diabetic foot ulcers. Galnobax is a topical gel NovaLead Pharma introduced in 2015 to treat diabetic foot ulcers.

The existence of a robust pipeline

Additionally, throughout the forecast period, a strong pipeline of innovative products to treat diabetic ulcers is anticipated to propel market expansion. For example, Phase III research of BioChaperone PDGF-BB, a new Platelet Derived Growth Factor (PDGF-BB) formulation, was started in India in 2014 by Adocia SA, a clinical-stage biotechnology company, to treat diabetic foot ulcers. Adocia SA reported completing the BioChaperone PDGF (BC PDGF) Phase 3 clinical trial in 2016. In the near future, introducing these experimental medications into emerging markets is anticipated to accelerate market expansion significantly.